We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
- Authors
Muss, Hyman B; Tu, Dongsheng; Ingle, James N; Martino, Silvana; Robert, Nicholas J; Pater, Joseph L; Whelan, Timothy J; Palmer, Michael J; Piccart, Martine J; Shepherd, Lois E; Pritchard, Kathleen I; He, Zhi; Goss, Paul E
- Abstract
National Cancer Institute of Canada Clinical Trials Group trial MA.17 randomly assigned 5,187 postmenopausal, hormone-receptor-positive patients with early breast cancer who completed 5 years of tamoxifen to receive either letrozole or placebo. At 30 months median follow-up, letrozole significantly improved disease-free survival (DFS) in all patients and overall survival (OS) in node-positive patients. Breast cancer incidence increases with age and more than 1,300 women age 70 years or older were enrolled onto MA.17, making it ideal to explore the benefits, toxicities, and quality of life (QOL) impact of letrozole on older women.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 12, p1956
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.12.6334